Baseline serum vitamin D assessment: essential pre-trial steps

And until investigators stop treating baseline 25-hydroxyvitamin D [25(OH)D] measurement as a checkbox on a screening form, every endpoint downstream — fracture reduction, infection rate, mood score, mortality — will inherit the analytical chaos of the assay that produced the number in the first place.

The numbers tell the story without sentiment. Unstandardized 25(OH)D assays show inter-method variability ranging from roughly 10% to 20%. That spread is not academic. It can flip 4% to 32% of enrolled participants across the deficiency threshold of <20 ng/mL (<50 nmol/L) without anyone changing a dose, adjusting a protocol, or moving a muscle. A trial that cannot reliably classify its own cohort is not a trial; it is a lottery wearing a case report form.

If your baseline 25(OH)D measurement cannot meet CV ≤ 10% and mean bias ≤ 5%, it is not a baseline — it is a guess with a unit attached.

The Role of 25(OH)D as a Primary Biomarker

Total serum 25(OH)D — the combined concentration of 25(OH)D2 and 25(OH)D3 — is, for practical purposes, the only biomarker worth defending when a trial sets out to evaluate vitamin D status. The reason is not glamorous: it is pharmacokinetic. 25(OH)D has a circulating half-life of approximately 2 to 3 weeks, long enough to integrate recent sun exposure and dietary intake into a stable serum signal, short enough to respond meaningfully to supplementation.

Contrast this with 1,25-dihydroxyvitamin D [1,25(OH)2D], the hormonally active form, which circulates at roughly a thousand-fold lower concentration, is tightly regulated by parathyroid hormone, calcium, and phosphate, and shifts dramatically in kidney disease. Its concentration tells you almost nothing about vitamin D stores in a generally healthy trial population. Yet 1,25(OH)2D keeps getting ordered, reported, and occasionally worshipped as if it were the relevant variable. It is not. The marker that survives the half-life test is the marker that goes on the case report form.

A practical consequence: every baseline draw in a vitamin D intervention trial should be specifically scheduled, fasting not strictly required, but standardized for season of collection, latitude of the recruitment site, and time since the participant's last high-dose supplement. Two people with identical "true" status can show wildly different 25(OH)D values depending on whether their blood was drawn in Reykjavík in March or in Málaga in August. Why would any analysis plan pretend otherwise?

Mitigating Analytical Bias Through Standardization

The Vitamin D Standardization Program (VDSP), launched in 2010, did the field an unusual favor: it wrote down the numbers. VDSP performance criteria demand an overall assay imprecision (coefficient of variation) of ≤ 10% and a mean bias of ≤ 5% relative to reference measurement procedures. These are not aspirational targets. They are the minimum bar for any 25(OH)D assay that wants to be taken seriously inside a clinical trial.

The trial design implication is direct. Investigators cannot outsource the laboratory decision to the local hospital and hope for the best. They must either:

1. Send baseline (and follow-up) samples to a laboratory certified under VDSP-equivalent traceable procedures, typically using LC-MS/MS anchored to NIST or Ghent University reference standards.

2. Run a parallel calibration study against a reference laboratory and apply a recalibration equation to all locally generated values before they enter the statistical model.

The first option is cleaner. The second is cheaper. Both beat the third, which is the default in far too many published trials: do nothing, report the unstandardized values, and hope no reviewer asks which immunoassay platform produced them. The hope is, historically, not well rewarded.

Inter-method variability of 10–20% is not a rounding error. It is a misclassification engine running at 4–32% across the cohort.

LC-MS/MS vs. Immunoassays: Precision in Participant Stratification

The argument for LC-MS/MS over conventional immunoassays is not a turf war between laboratory disciplines. It is a question of what the instrument can actually distinguish. LC-MS/MS resolves structural epimers (the 3-epi-25(OH)D3 form, prominent in infant samples but not absent in adults), separately quantifies 25(OH)D2 and 25(OH)D3, and avoids the cross-reactivity that plagues antibody-based platforms with vitamin D metabolites like 24,25-dihydroxyvitamin D.

Immunoassays, by contrast, are fast, cheap, and routinely wrong in ways that compound across thousands of samples. In the same participant, two immunoassay platforms from different manufacturers — both CLIA-certified, both used in real-world hospital labs — can disagree on whether that participant is "deficient" or "replete." Multiply that across a stratified randomization block and the stratification itself becomes unreliable. What exactly is being stratified, then?

The cost differential is real. It is also the wrong place to economize. Trial budgets routinely absorb six-figure expenditure on imaging, central reading, and adjudicated endpoint committees, then pinch pennies on the laboratory step that determines which arm of the trial each participant belongs in. The mismatch is hard to defend in a methods section, and harder to defend in a replication attempt.

Retrospective Calibration for Banked Serum Samples

Sometimes the trial has already happened. The serum is sitting in a −80 °C freezer, and the question is whether the published results can be salvaged. VDSP addressed this directly by publishing a methodology for retrospective laboratory standardization of 25(OH)D values in banked samples. The procedure is not magic — it is statistics plus traceability.

The core requirement: a calibration set of 40 to 50 single-donor serum samples, each measured by both the original (unstandardized) assay and a reference measurement procedure traceable to international standards. The resulting regression equation is then applied to every banked value from the trial, transforming a noisy historical dataset into one that can be compared, pooled, and meta-analyzed against modern standardized studies.

This is the path the field has taken with several landmark datasets, and it is the reason older 25(OH)D cutoffs can sometimes be re-evaluated without rerunning the original cohort. Two practical notes for investigators considering retrospective standardization:

• The 40–50 donor calibration set should span the expected analytical range of the trial — including low, medium, and high 25(OH)D values — otherwise the regression equation extrapolates beyond its validated window and produces confident nonsense.
• Freeze-thaw cycles and storage duration degrade 25(OH)D; samples stored for more than a decade should be re-validated before the calibration is applied, or at minimum the storage conditions should be reported transparently in the supplement.

Navigating Clinical Guidelines and Screening Ethics

A final piece of the pre-trial architecture that investigators often fumble: the difference between a clinical screening assay and a research assay. The Endocrine Society's 2024 updated clinical practice guidelines recommend against routine 25(OH)D screening in general populations without specific clinical indications. That recommendation is correct for routine care — it conserves resources, avoids overdiagnosis, and addresses the well-documented problem of population-wide screening identifying "deficient" individuals who would never become patients.

A clinical trial is not routine care. The same guideline framework acknowledges that testing is appropriate when there is a defined clinical or research indication, and a vitamin D intervention trial is, by definition, such an indication. Trial participants are not a general population; they are a selected cohort with consent, an intervention plan, and outcomes to be measured. The ethical and methodological obligation to measure their baseline 25(OH)D accurately is therefore higher, not lower, than in clinical practice — even if the casual reader of the guideline might form the opposite impression.

This cuts both ways. Investigators should not invoke "Endocrine Society guidance" to avoid screening in a trial where stratification depends on it. Nor should they extrapolate trial-grade assay precision onto routine clinical testing, where cost and throughput legitimately dominate the laboratory decision. The two contexts answer different questions.

The Verdict

Baseline serum vitamin D assessment is not a routine lab test dressed up in trial paperwork. It is the analytical anchor of the entire study. A protocol that sends participants' baseline blood to an unstandardized immunoassay, skips VDSP-equivalent recalibration, and ignores season and latitude in the analysis plan is building its conclusions on a substrate that varies by 10% to 20% before the first capsule is opened. Up to a third of the cohort can be misclassified before randomization begins.

The pre-trial checklist, written without softening:

• Specify total 25(OH)D as the primary baseline biomarker, not 1,25(OH)2D.
• Select a laboratory whose assay meets VDSP performance criteria (CV ≤ 10%, bias ≤ 5%).
• Prefer LC-MS/MS or a VDSP-aligned immunoassay platform; if cost forces immunoassay use, build in a recalibration step against the reference procedure.
• For banked historical samples, apply VDSP retrospective calibration using a 40–50 donor reference set covering the full analytical range.
• Document season, latitude, recent supplement use, and storage conditions for every sample.
• Do not conflate clinical screening guidance (against routine population testing) with research-grade measurement obligation.
• Report which assay platform generated the data, and whether it was traceable to a reference measurement procedure.

Any trial that omits these steps is welcome to publish its results. The readers will simply know what to make of them.